首页> 外文期刊>Liver international >Abnormal liver tests in patients hospitalized with Coronavirus disease 2019: Should we worry?
【24h】

Abnormal liver tests in patients hospitalized with Coronavirus disease 2019: Should we worry?

机译:2019冠状病毒病住院患者的肝脏检查异常:我们应该担心吗?

获取原文
获取原文并翻译 | 示例
获取外文期刊封面目录资料

摘要

While several studies from China have reported COVID-19-related liver injury, there are currently no data on liver dysfunction in hospitalized COVID-19 patients in Europe. The aim of this study was to describe the prevalence and predictive value of abnormal liver function in patients hospitalized with COVID-19. This was a retrospective cohort study of confirmed COVID-19 patients hospitalized in two referral hospitals in France. Clinical, biological and radiological data were collected and analysed. In all, 234 patients confirmed to have COVID-19 by RT-PCR were included. Liver function was abnormal in 66.6 of patients on admission. In multivariate logistic regression, abnormal liver test on admission were associated with in-hospital aggravation (OR = 4.1, 95 CI 1.5-10.8;P = .004) and mortality (OR 3.3; 95 CI = 1.04-10.5;P = .04). This study of liver tests in a European COVID-19 population confirms a high prevalence of abnormal liver tests on admission that are predictive of severe disease course and higher in-hospital mortality.
机译:虽然来自中国的几项研究报告了 COVID-19 相关的肝损伤,但目前没有关于欧洲住院 COVID-19 患者肝功能障碍的数据。本研究的目的是描述 COVID-19 住院患者肝功能异常的患病率和预测价值。这是一项回顾性队列研究,对象是在法国两家转诊医院住院的确诊 COVID-19 患者。收集并分析了临床、生物学和放射学数据。总共纳入了 234 名通过 RT-PCR 确诊患有 COVID-19 的患者。66.6%的患者入院时肝功能异常。在多因素logistic回归中,入院时肝功能检查异常与住院加重相关(OR=4.1,95%CI 1.5-10.8;P = .004)和死亡率(OR 3.3;95% CI = 1.04-10.5;P = .04)。这项针对欧洲 COVID-19 人群的肝脏检查研究证实,入院时肝脏检查异常的患病率很高,这些检查可预测严重病程和较高的院内死亡率。

著录项

获取原文

客服邮箱:kefu@zhangqiaokeyan.com

京公网安备:11010802029741号 ICP备案号:京ICP备15016152号-6 六维联合信息科技 (北京) 有限公司©版权所有
  • 客服微信

  • 服务号